Truist Securities Reiterates Buy on Inspire Medical Systems, Maintains $340 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Richard Newitter has reiterated a 'Buy' rating on Inspire Medical Systems (NYSE:INSP) and maintained a price target of $340.
October 02, 2023 | 4:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Inspire Medical Systems (NYSE:INSP) has had its 'Buy' rating reiterated by Truist Securities, with a maintained price target of $340.
The reiteration of a 'Buy' rating by Truist Securities indicates a positive outlook for Inspire Medical Systems. The maintained price target of $340 suggests that the analyst believes the stock has potential for growth. This could positively impact the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100